top of page
website background_edited_edited_edited.jpg

NI LAB

We leverage on novel nucleic acids modification techniques and nanotechnologies to improve mRNA therapeutics (RNA vaccines, gene editing)

Our Services

Recent Highlights

mol ther dec 2025.jpg

Co-delivering a cGAS agonist and antigen via LNPs potentiates cancer immunotherapy


Dec 9, 2025                                         Impact factor: 6.1                                      

Wu et al. developed a lipid nanoparticle (LNP) platform that co-delivers an oligonucleotide-based cyclic GMP–AMP synthase (cGAS) agonist, Svg3, together with peptide or mRNA antigens to enhance cancer vaccine efficacy. By activating the cGAS pathway and inducing endogenous 2′3′-cGAMP production, Svg3 drives sustained STING signaling and robust type I interferon responses, thereby improving antigen presentation and promoting strong antigen-specific CD8⁺ T cell expansion. When co-encapsulated in LNPs, Svg3 ensures synchronized delivery of antigen and innate stimuli, enhancing immunogenicity and overcoming tumor-induced immune suppression. In murine colorectal and HPV-associated tumor models, Svg3-containing vaccines synergized with PD-1 blockade to achieve superior tumor control. This cGAS-targeted LNP strategy offers a promising approach to potentiate cancer vaccines and expand the therapeutic benefit of immune checkpoint blockade.

Read more in Molecular Therapy Nucleic Acid.

loader,gif

Targeted biomimetic fusogenic liposome enhances tumor accumulation, penetration, and therapeutic efficacy of siRNA therapeutics

Oct 12, 2025                                         Impact factor: 10.2 

Zhao et al. developed a biomimetic fusogenic liposomal platform to enhance siRNA-based cancer therapy by promoting macrophage-mediated phagocytosis through coordinated silencing of CD47 and PLK1. The liposomes exhibited deep tumor penetration and selective tumor cell targeting, enabling efficient cytosolic delivery of siRNAs. CD47 siRNA suppressed the “don’t eat me” signal by downregulating CD47 expression, while PLK1 siRNA induced apoptosis and enhanced the “eat-me” signal via calreticulin translocation to the cell surface. This dual-silencing approach significantly improved macrophage phagocytosis and antitumor efficacy in a 4T1 tumor-bearing mouse model. The biomimetic fusogenic liposome thus represents a promising therapeutic strategy for triple-negative breast cancer by amplifying innate immune clearance and suppressing tumor growth.

Read more in Materials Today Bio.

mat td bio 2025.jpg
bmemat sep 2025.jpg

Multifunctional H2S-activated metal-organic framework systems for targeted colorectal cancer imaging and synergistic copper-induced tumor regression

Sep 4, 2025                                         Impact factor: 15.5 

Zheng et al. developed a hydrogen sulfide (H₂S)-activated metal–organic framework (MOF) nanoplatform for targeted colorectal cancer theranostics. Leveraging the elevated H₂S levels in colorectal tumors, the Cu-MOF system rapidly responded to H₂S to generate copper sulfide with strong near-infrared absorption and enhanced photoacoustic (PA) signals. This activation enabled precise tumor imaging and synergistic copper-induced tumor regression. Mechanistically, the Cu-MOF nanosystem reduced protein lipoylation and Fe–S cluster protein (FDX1) levels, inducing cuproptosis and enhancing therapeutic efficacy. In vivo studies demonstrated potent tumor inhibition in an orthotopic colon cancer model with minimal toxicity. This H₂S-responsive MOF design offers a promising strategy for multifunctional PA/CDT/PTT/cuproptosis-based colorectal cancer theranostics.

Read more in BMEMat.

微信图片_20231214134050.png

JOIN US AT NUS!

We are constantly seeking young researchers and students to join our lab! 

 

If you are interested in joining us or have any inquiries, please contact Dr Ni at qqian.ni@nus.edu.sg

Supports for work in Ni's lab

  • NMRC YIRG

  • NRF Competitive Research Programme

  • NMRC IRG

  • WUXI APPTEC-NUS

  • MOE-TIER

  • NUS Start-up

  • NUS-Shawn Chen Lab

Patent

  • NUS invention ID (2023-019)

  • NUS invention ID (2022-171)
     

Useful Links

NUS
NUS YLL
prof chen tnt logo
google scholar

Copyright © 2023 Dr Ni Qianqian's Lab. All Rights Reserved.

Ni's Lab-NUS logo
nuslogo
bottom of page